Impact of Upadacitinib on Reducing Pain in Patients Across the Axial Spondyloarthritis Spectrum: A Post Hoc Analysis of the Phase 2/3 SELECT-AXIS Studies

Psoriatic Arthritis

Efficacy of risankizumab across GRAPPA domains in psoriatic arthritis: a pooled analysis of patients from the phase 3 KEEPsAKE 1 and 2 studies

RMD Open

Coates LC, Blanco R, Behrens F, Ogdie A, Van den Bosch F, Ranza R, Klionsky Y, Soliman AM, Chen M, Coombs D, Shi L, Urbanik JR, Iyile T, Lippe R, Gossec L

doi: 10.1136/rmdopen-2025-005522

Rheumatoid Arthritis

Effects of upadacitinib or adalimumab on pain in rheumatoid arthritis and psoriatic arthritis: results from randomised phase 3 studies

RMD Open

Taylor PC, Kavanaugh A, Bessette L, Fautrel B, Takeuchi T, Garrison A, Gao T, Lippe R, Caballero D, Phillips C, Mease PJ

doi: 10.1136/rmdopen-2025-005867

Psoriasis

A Phase 3, Randomized, Double-blind, Active-controlled Clinical Study to Compare BAT2206, a Ustekinumab Biosimilar, with Ustekinumab Reference Product in Patients with Moderate-to-severe Psoriasis: Treatment Period 2 Results (Post Week 28 to Week 52)

J Am Acad Dermatol

Man X, Zaharieva K, Pulka G, Żebrowska A, Deng Y, Mekokishvili L, Yang X, Qi Y, Gu C, Dong Q, Zheng M

doi: 10.1016/j.jaad.2025.08.005

Psoriatic Arthritis

Highly selective tyrosine kinase 2 inhibition with zasocitinib (TAK-279) improves outcomes in patients with active psoriatic arthritis: a randomised phase 2b study

Ann Rheum Dis

Kivitz A, Baraliakos X, Muensterman ET, Kavanaugh A, van der Heijde D, Klimiuk PA, Valenzuela G, Dokoupilova E, Poirier G, Srivastava B, Dasen S, Zhang X, Hong T, Chen J, Pothula P, Weng HH, Trivedi M, Lertratanakul A

doi: 10.1016/j.ard.2025.05.023

Psoriasis

Highly selective, allosteric inhibition of TYK2 with oral ESK-001 in patients with moderate-to-severe plaque psoriasis: Results from STRIDE, a 12-week, randomized, double-blinded, placebo-controlled, dose-ranging Phase 2 study

J Am Acad Dermatol

Blauvelt A, Arenberger P, Sauder MB, Couvillion M, Rubio RG, Vlahakis NE, Ucpinar S, Ma G, Hitraya E, Tilley MK, Papp KA, STRIDE investigators

doi: 10.1016/j.jaad.2025.07.013

Psoriatic Arthritis

Access, Effectiveness, Safety And Survival Of Secukinumab In Patients With Axial Spondyloarthritis And Axial Psoriatic Arthritis: Real-Life Study In Argentina

J Rheumatol

Martire MV, Marin J, Maldonado Ficco H, Benegas M, Giorgis P, Vila D, Isnardi CA, Gamba MJ, Flores Trejo JF, Perez-Alamino R, Chemez AJ, Ferreyra Garrott L, Cosatti MA, Buschiazzo EA, Correa MLA, Aguila Maldonado R, Manases Roldan B, Lizarraga C, Alfaro MA, Morbiducci J, Ingolotti LV, Pendón G, Nieto RE, Velloso MS, Martinez Muñoz A, Lloves Schenone N, Zamora NV, Saturansky E, Costi AC, Haye Salinas MJ, Airoldi CA, Granel A

doi: 10.3899/jrheum.2024-1185

Psoriatic Arthritis

Bimekizumab safety and efficacy in patients with psoriatic arthritis: 3-year results from two phase 3 studies

Rheumatology (Oxford)

Gossec L, Coates LC, Landewé RBM, Mease PJ, Merola JF, Ritchlin CT, Tanaka Y, Asahina A, Proft F, Goldammer N, Manente M, Ink B, Bajracharya R, Coarse J, McInnes IB

doi: 10.1093/rheumatology/keag118

Psoriasis

Bimekizumab efficacy and safety in Chinese patients with psoriasis in the BE SHINING Phase 3 study

J Eur Acad Dermatol Venereol

Cai L, Man XY, Wang J, Wei A, Chen Y, Deherder D, Gao J, Hoepken B, Sun W, Lei T, Zhang J, BE SHINING Study Group

doi: 10.1111/jdv.70350

Further Publications Dermatology

Post-exposure prophylaxis regimen of rabies monoclonal antibody and vaccine in category 3 potential exposure patients: a phase 4, open-label, randomised, active-controlled trial

Lancet

Kulkarni PS, Potey AV, Kapse D, Bhamare C, Gawande A, Munshi R, Pawar S, Gogtay NJ, Agarwal A, Tambe M, Thakre S, Samuel CJ, Khan SMS, S RH, Rana D, Singh N, Kamath V, Bhalla HL, Poonawalla CS, Mani RS, Gunale B, RAB-04 study group

doi: 10.1016/S0140-6736(25)00735-4

Related content

Efficacy of risankizumab across GRAPPA domains in psoriatic arthritis: a pooled analysis of patients from the phase 3 KEEPsAKE 1 and 2 studies

Effects of upadacitinib or adalimumab on pain in rheumatoid arthritis and psoriatic arthritis: results from randomised phase 3 studies

A Phase 3, Randomized, Double-blind, Active-controlled Clinical Study to Compare BAT2206, a Ustekinumab Biosimilar, with Ustekinumab Reference Product in Patients with Moderate-to-severe Psoriasis: Treatment Period 2 Results (Post Week 28 to Week 52)

Highly selective tyrosine kinase 2 inhibition with zasocitinib (TAK-279) improves outcomes in patients with active psoriatic arthritis: a randomised phase 2b study

Highly selective, allosteric inhibition of TYK2 with oral ESK-001 in patients with moderate-to-severe plaque psoriasis: Results from STRIDE, a 12-week, randomized, double-blinded, placebo-controlled, dose-ranging Phase 2 study

Access, Effectiveness, Safety And Survival Of Secukinumab In Patients With Axial Spondyloarthritis And Axial Psoriatic Arthritis: Real-Life Study In Argentina

Bimekizumab safety and efficacy in patients with psoriatic arthritis: 3-year results from two phase 3 studies

Bimekizumab efficacy and safety in Chinese patients with psoriasis in the BE SHINING Phase 3 study

Post-exposure prophylaxis regimen of rabies monoclonal antibody and vaccine in category 3 potential exposure patients: a phase 4, open-label, randomised, active-controlled trial